State Street’s SAB Biotherapeutics SABS Stock Holding History

State Street’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.07M	Buy	530,831 +456,600	+615%	+$1.7M	﹤0.01%	3325
2026 Q1	$284K	Buy	74,231 +61,109	+466%	+$244K	﹤0.01%	3801
2025 Q4	$49.1K	Buy	+13,122	New	+$43.2K	﹤0.01%	4151
2024 Q1	–	Sell	-8,124	Closed	-$55.9K	–	4398
2023 Q4	$55.9K	Hold	8,124	–	–	﹤0.01%	4177
2023 Q3	$51.2K	Hold	8,124	–	–	﹤0.01%	4284
2023 Q2	$67.4K	Hold	8,124	–	–	﹤0.01%	4330
2023 Q1	$35.7K	Hold	8,124	–	–	﹤0.01%	4586
2022 Q4	$47.9K	Hold	8,124	–	–	﹤0.01%	4567
2022 Q3	$57K	Hold	8,124	–	–	﹤0.01%	4628
2022 Q2	$118K	Buy	8,124 +3,890	+92%	+$81.7K	﹤0.01%	4449
2022 Q1	$159K	Buy	4,234 +3,004	+244%	+$139K	﹤0.01%	4467
2021 Q4	$96K	Buy	+1,230	New	+$115K	﹤0.01%	4590

Other funds holding SABS

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street's SABS Position: Q2 2026 in Review

State Street increased its SAB Biotherapeutics (SABS) stake by 615% in Q2 2026, buying an estimated $1.7M and bringing the position to 530,831 shares worth $2.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3325.

State Street first reported a position in SABS in Q4 2021 and has held it in 12 quarters since. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

State Street held 530,831 shares of SAB Biotherapeutics worth $2.07M as of Q2 2026.
State Street bought 456,600 SAB Biotherapeutics shares in Q2 2026, an estimated $1.7M.
SAB Biotherapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3325 holding.
State Street first reported a position in SAB Biotherapeutics in Q4 2021 and has held it in 12 quarters since.
87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.